Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T Cell Therapy has emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects.
CAR-T Cell Therapy – Current Market Landscape
Presently, over 170 companies are engaged in the development of more than 970 early and late-stage CAR T Therapy solutions, worldwide. More than 80% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, CD19 and BCMA have emerged as the most popular target antigens.
Partnerships and Collaborations
A rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in the CAR T therapy domain; maximum number of such deals were signed in 2021. Majority of the partnership instances are intracontinental. Additionally, close to 50% of the total number of partnerships have been signed between the players based in North America. Further, for majority of the intercontinental agreements, CAR T Cell Therapy companies headquartered in Europe have collaborated with players based in North America.
CAR-T Cell Therapy – Funding and Investments
Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested close to USD 25 billion, across 260+ instances, during the period 2000-2022
CAR-T Cell Therapy – Patent Analysis
Majority of the patents in this domain are patent applications (84%), followed by granted patents (13%). In addition, most of the patents (35%) were filed / granted in Asia-Pacific. This is followed by patents filed / granted in North America (30%).
Market Forecast and Opportunity Analysis
In the long-term, the overall projected opportunity is likely to be well distributed across key market segments, including type of therapy, indications, target antigen, key players and geographical regions; the market is expected to grow at a CAGR of ~20% by 2035.
Conclusion: Over the past few years, CAR-T cell therapy has been successful in carving out a significant niche in the pharmaceutical market. A number of such targeted therapies have already been approved whilst a robust development pipeline indicates that the CAR T Cell Therapy market is likely to grow at a steady pace in the foreseen future. Moreover, the ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipelines of companies engaged in this market. Currently, several industry and non-industry players are focused on the development of technologies that are capable of overcoming the existing roadblocks in the production / adoption of CAR T therapy. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the CAR-T cell immunotherapies market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.
You can also download the SAMPLE REPORT on CAR T therapies by Roots Analysis.